# Ian R Watson

## List of Publications by Citations



| | | | |
|---|---|---|---|
| 36 papers | 5,747 citations | 22 h-index | 37 g-index |
| 37 ext. papers | 7,017 ext. citations | 14.2 avg, IF | 4.86 L-index |

| # | Paper | IF | Citations |
|---|---|---|---|
| 36 | Genomic Classification of Cutaneous Melanoma. *Cell*, **2015**, 161, 1681-96 | 56.2 | 1807 |
| 35 | A landscape of driver mutations in melanoma. *Cell*, **2012**, 150, 251-63 | 56.2 | 1799 |
| 34 | Melanoma genome sequencing reveals frequent PREX2 mutations. *Nature*, **2012**, 485, 502-6 | 50.4 | 555 |
| 33 | Emerging patterns of somatic mutations in cancer. *Nature Reviews Genetics*, **2013**, 14, 703-18 | 30.1 | 366 |
| 32 | Classifying BRAF alterations in cancer: new rational therapeutic strategies for actionable mutations. *Oncogene*, **2018**, 37, 3183-3199 | 9.2 | 164 |
| 31 | NEDD8 pathways in cancer, Sine Quibus Non. *Cancer Cell*, **2011**, 19, 168-76 | 24.3 | 127 |
| 30 | The RAC1 P29S hotspot mutation in melanoma confers resistance to pharmacological inhibition of RAF. *Cancer Research*, **2014**, 74, 4845-4852 | 10.1 | 111 |
| 29 | Mdm2-mediated NEDD8 modification of TAp73 regulates its transactivation function. *Journal of Biological Chemistry*, **2006**, 281, 34096-103 | 5.4 | 86 |
| 28 | Suppression of hypoxia-inducible factor 2alpha restores p53 activity via Hdm2 and reverses chemoresistance of renal carcinoma cells. *Cancer Research*, **2009**, 69, 9056-64 | 10.1 | 74 |
| 27 | Why is melanoma so metastatic?. *Pigment Cell and Melanoma Research*, **2014**, 27, 19-36 | 4.5 | 69 |
| 26 | Immature Low-Density Neutrophils Exhibit Metabolic Flexibility that Facilitates Breast Cancer Liver Metastasis. *Cell Reports*, **2019**, 27, 3902-3915.e6 | 10.6 | 68 |
| 25 | Ablation of adipocyte creatine transport impairs thermogenesis and causes diet-induced obesity. *Nature Metabolism*, **2019**, 1, 360-370 | 14.6 | 63 |
| 24 | Ubiquitin and ubiquitin-like modifications of the p53 family. *Neoplasia*, **2006**, 8, 655-66 | 6.4 | 48 |
| 23 | Loss of VHL confers hypoxia-inducible factor (HIF)-dependent resistance to vesicular stomatitis virus: role of HIF in antiviral response. *Journal of Virology*, **2006**, 80, 10712-23 | 6.6 | 46 |
| 22 | Eukaryotic translation elongation factor 1-alpha 1 inhibits p53 and p73 dependent apoptosis and chemotherapy sensitivity. *PLoS ONE*, **2013**, 8, e66436 | 3.7 | 45 |
| 21 | Molecular characterisation of cutaneous melanoma: creating a framework for targeted and immune therapies. *British Journal of Cancer*, **2016**, 115, 145-55 | 8.7 | 43 |
| 20 | Chemotherapy induces NEDP1-mediated destabilization of MDM2. *Oncogene*, **2010**, 29, 297-304 | 9.2 | 41 |

| | | | |
|---|---|---|---|
| 19 | The genetic heterogeneity and mutational burden of engineered melanomas in zebrafish models. *Genome Biology*, **2013**, 14, R113 | 18.3 | 33 |
| 18 | MAPK Pathway Inhibitors Sensitize BRAF-Mutant Melanoma to an Antibody-Drug Conjugate Targeting GPNMB. *Clinical Cancer Research*, **2016**, 22, 6088-6098 | 12.9 | 30 |
| 17 | Dual MAPK Inhibition Is an Effective Therapeutic Strategy for a Subset of Class II BRAF Mutant Melanomas. *Clinical Cancer Research*, **2018**, 24, 6483-6494 | 12.9 | 30 |
| 16 | Regulatory feedback loop between TP73 and TRIM32. *Cell Death and Disease*, **2013**, 4, e704 | 9.8 | 26 |
| 15 | Expression of p53 in renal carcinoma cells is independent of pVHL. *Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis*, **2005**, 578, 23-32 | 3.3 | 22 |
| 14 | Oncolytic targeting of renal cell carcinoma via encephalomyocarditis virus. *EMBO Molecular Medicine*, **2010**, 2, 275-88 | 12 | 19 |
| 13 | Multi-omic analysis reveals significantly mutated genes and DDX3X as a sex-specific tumor suppressor in cutaneous melanoma.. *Nature Cancer*, **2020**, 1, 635-652 | 15.4 | 13 |
| 12 | Neutrophil oxidative stress mediates obesity-associated vascular dysfunction and metastatic transmigration.. *Nature Cancer*, **2021**, 2, 545-562 | 15.4 | 13 |
| 11 | Use of clinical next-generation sequencing to identify melanomas harboring SMARCB1 mutations. *Journal of Cutaneous Pathology*, **2015**, 42, 308-17 | 1.7 | 11 |
| 10 | Mutations in the IFN□JAK-STAT Pathway Causing Resistance to Immune Checkpoint Inhibitors in Melanoma Increase Sensitivity to Oncolytic Virus Treatment. *Clinical Cancer Research*, **2021**, 27, 3432-3442 | 12.9 | 10 |
| 9 | C3a elicits unique migratory responses in immature low-density neutrophils. *Oncogene*, **2020**, 39, 2612-2623 | 9.2 | 7 |
| 8 | Dynamic Neutrophil-to-Lymphocyte Ratio: A Novel Prognosis Measure for Triple-Negative Breast Cancer. *Annals of Surgical Oncology*, **2020**, 27, 4028-4034 | 3.1 | 7 |
| 7 | p66ShcA functions as a contextual promoter of breast cancer metastasis. *Breast Cancer Research*, **2020**, 22, 7 | 8.3 | 4 |
| 6 | Reprogramming of Nucleotide Metabolism Mediates Synergy between Epigenetic Therapy and MAP Kinase Inhibition. *Molecular Cancer Therapeutics*, **2021**, 20, 64-75 | 6.1 | 3 |
| 5 | Melanomas with concurrent BRAF non-p.V600 and NF1 loss-of-function mutations are targetable by BRAF/MEK inhibitor combination therapy.. *Cell Reports*, **2022**, 39, 110634 | 10.6 | 3 |
| 4 | Spatially mapping the immune landscape of melanoma using imaging mass cytometry.. *Science Immunology*, **2022**, 7, eabi5072 | 28 | 2 |
| 3 | The clinical significance of adenomatous polyposis coli (APC) and catenin Beta 1 (CTNNB1) genetic aberrations in patients with melanoma.. *BMC Cancer*, **2022**, 22, 38 | 4.8 | 1 |
| 2 | Melanomics: Comprehensive Molecular Analysis of Normal and Neoplastic Melanocytes **2019**, 181-224 | | |

1 Melanomics: Comprehensive Molecular Analysis of Normal and Neoplastic Melanocytes **2018**, 1-44